louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06234202: The Effect of a Bioactive Fabric Sleeve
Official title: The Effect of a Bioactive Fabric Sleeve on Recovery in Division I Collegiate Baseball Players
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Recovery
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: Challenger Health, LLC
First posted: 2024-01-31
Enrollment: 13
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: In-season pitch volume have been shown to relate to arm soreness in collegiate baseball players. Arm soreness is a common ailment following a pitching appearance due to the adaptation to soft tissue in response to a repetitive load to the throwing arm. Specifically, ongoing and accumulated fatigue and soreness to the flexor pronator mass region of the arm may be a predecessor for UCL injury. Different recovery modalities such as a bioactive fabric sleeve may give pitchers a recovery advantage throughout a baseball season. The primary purpose of this study is to determine if there is a difference in subjective soreness of the flexor pronator mass the day following a game pitching appearance using a sleeve with bioactive fabric which potentially improves cellular function versus a control sleeve.


Eligibility criteria: Inclusion Criteria:

* Stanford Baseball Player

Exclusion Criteria:

* None

Primary outcomes:
measure: Subjective Soreness Score
timeFrame: Baseline through 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University
state: California
Study officials:
affiliation: Stanford University
name: Michael Freehill, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02739802: 18751-Sun Protection Factor Assay.
Official title: Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agents
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-04-15
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the Sun Protection Factor (SPF) efficacy on human skin.


Eligibility criteria: Inclusion Criteria: - Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing. - Male or female - Aged between 18-70 years old. - Good health - Signed and dated Informed Consent Form - Signed and dated Health Insurance Portability and Accountability Authorization (HIPAA) Form - An unambiguous MED or MPPD (Minimal Persistent Pigment Darkening Dose) Exclusion Criteria: - Subjects on test at any other research laboratory or clinic. - Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light. - PRe-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study. - Pre-existing other medical conditions (e.g. adult asthma. diabetes). - Treatment with antihistamines or corticosteroids within one week prior to initiation of the test. - Treatment with antibiotics within two weeks prior to initiation of the test - Chronic medication which could affect the results of the study. - Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose(MED)
timeFrame: Up to 15 minutes
measure: Minimal Persistent Pigment Darkening Dose (MPPD)
timeFrame: Up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT06434402: A Virtual, Group-Based, Expressive Writing Intervention for Survivors of Adolescent and Young Adult Cancer
Official title: A Virtual, Group-Based, Expressive Writing Intervention for Survivors of Adolescent and Young Adult Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cancer
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2024-05-30
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: To learn more about the experiences of adolescent and young adult cancer survivors and investigate whether a group-based writing intervention can help to improve quality of life of adolescent and young adult cancer survivors.

Detailed description: Primary Objective:

To evaluate the feasibility of a virtual, group-based expressive writing intervention for survivors of adolescent and young adult cancer.

Secondary Objective:

To preliminarily assess the impact of the study for cancer survivors.

Eligibility criteria: Inclusion criteria:

* Age 15-39 years at cancer diagnosis
* Age 18-39 years at study entry
* Within 5 years of diagnosis of stage II-IV cancer
* Completed active treatment (participants receiving maintenance therapy remain eligible)
* No evidence of disease
* Can speak, read, and write in English.

Exclusion criteria:

* Nonmelanoma skin cancer
* Major mental health disorder (e.g., schizophrenia or bipolar disorder \[determined from patient records or self-disclosure\])
* No internet access.

Primary outcomes:
measure: Study Completion Rate
timeFrame: At 1 month follow-up
measure: Intervention Adherence Rate
timeFrame: At the end of intervention (week 8)
Secondary outcomes:
measure: Functional Assessment of Cancer Therapy-General
timeFrame: Baseline, and 1- and 3-month follow-up
measure: Perceived Stress
timeFrame: Baseline, and 1- and 3-month follow-up
measure: Coping self-efficacy
timeFrame: Baseline, and 1- and 3-month follow-up
measure: Impact of Event Scale
timeFrame: Baseline, and 1- and 3-month follow-up
measure: Common Humanity & Self-Kindness
timeFrame: Baseline, and 1- and 3-month follow-up
measure: Posttraumatic growth
timeFrame: Baseline, and 1- and 3-month follow-up
Other outcomes:
Locations:
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Qian Lu, MD,PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03123302: Our Anesthesia Experience During MRI Scan
Official title: Our Anesthesia Experience During MRI Scan
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epileptic Seizure
Intracranial Tumor
Intracranial Hypertension
Intracranial Aneurysm
Vertebra; Anomaly
Keywords: MRI scan, sedation, epilepsia
Lead sponsor: Akdeniz University
Sponsor class: OTHER
First posted: 2017-04-21
Enrollment: 977
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients undergoing MRI scan wth sedation anesthesia and giving written informed consent.

Brief summary: In this study we aim to investigate the relationship between our anesthesia practice and post procedure complications after MRI scanning with sedation. This is a retrospective, single center observational study. All patients undergoing MRI scan during the study period will be included.

Detailed description: In this study we aim to investigate the influence of patient characteristics and anesthesia choice on possible complications in patients undergoing MRI under sedation retrospectively.

After one of the routine sedation protocol used in our department was chosen and applied according to the physical status of the patient and the physicians decision, the datas of the patients will be recruited to the study from the medical records . Patient characteristics (age, gender, weight, height), ASA (American Society of Anethesiology) classification, associated diseases will be recorded . After the procedure was completed all the complications during the 2 hours waiting period in the recovery room will be recorded from the medical records. All the complşcation and recovery times will be recorded from the medical records. Whether the patient received radiocontrast material or not will also be recorded. The patients will be called by phone, and will be questioned for the complications, any epileptic seizure attack, or increase in the number of seizures, any admission to emergency room or any in patient admission to the hospital will be recorded which developed in the first week after the procedure.

Eligibility criteria: Inclusion Criteria:All patients undergoing MRI scan wth sedation anesthesia and giving written informed consent.

Exclusion Criteria: patients refusal to be studied.

-

Primary outcomes:
measure: Patient characteristics anesthesia choice and possible complications during MRI anesthesia.
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Antalya
country: Turkey
facility: AkdenizU
Study officials:
affiliation: Akdeniz University Hospital
name: Ilker O Aycan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02184702: Effects of Shoulder Edema on Intubated Tube in Patients Undergoing Shoulder Arthroscopy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arthroscopy
Lead sponsor: Inje University
Sponsor class: OTHER
Collaborators: name: Fresenius Kabi Korea
First posted: 2014-07-09
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patints who undergoing shoulder arthroscopy American Society of Anesthesiologists (ASA) 1,2

Brief summary: Intubation is needed in general anesthesia and appropriate cuff pressure is important to avoid trauma or postoperative sore throat and aspiration. Shoulder arthroscope uses some amount of irrigation fluid and it can influence to cuff pressure. Therefore, we will measure cuff pressure during shoulder arthroscope.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) 1,2 Age 20-65

Exclusion Criteria:

* emergency operation anticipated difficult intubation chronic obstructive lung disease recent upper respiratory infection

Primary outcomes:
measure: Direct intracuff pressure measurement technique using manometer
timeFrame: every one hour during operarion
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Inje University Seoul Paik Hospital, Seoul, Korea
state: Jung-Gu
Study officials:
affiliation: Inje University Seoul Paik Hospital, Seoul, Korea
name: Sira Bang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00818402: Non-small Cell Lung Cancer and Quality of Life
Official title: Treatment of Non-small Cell Lung Cancer -Effects on Quality of Life and Symptom Control
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non Small Cell Lung Cancer
Keywords: Quality of life
symptoms
Lead sponsor: University of Turku
Sponsor class: OTHER
First posted: 2009-01-07
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patients treated in the clinic of respiratory medicine in Turku, Finland

Brief summary: The principal objective is to study clinical observations, symptoms and quality of life of non-small-cell lung cancer (NSCLC) patients undergoing specific non-operative treatment for cancer, including chemotherapy and radiotherapy.


Eligibility criteria: Inclusion Criteria:

* Patients with verified NSCLC
* after the NSCLC diagnosis has been confirmed prior to first chemotherapy or radiotherapy
* Finnish speaking patients
* aged 18 years or more
* Written informed consent has to be signed

Exclusion Criteria:

* Patients not consenting to participate in the study
* patients not able to communicate sufficiently
* cancer type is other than non-small-cell lung cancer

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06291402: Nasal Packing Duration and Development of Pharyngitis After Septorhinoplasty Surgery
Official title: Nasal Packing Duration and Its Role in the Development of Pharyngitis After Septorhinoplasty Surgery: A Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Rhinitis
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
Collaborators: name: Benha University
First posted: 2024-03-04
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 100 ASA I and II patients aged from 20 to 40 years old will undergo septorhinoplasty in Benha university hospitals

Brief summary: Septoplasty or septal reconstruction is a corrective surgical procedure performed to straighten the nasal septum. It may be associated with numerous complications. To minimize these complications, both nasal cavities are frequently packed with different types of nasal packing. In our study we will try to find relationship between duration of nasal packing and postrhinoplasty sore throat and pharyngitis.

Detailed description: Nasal packing affects swallowing by different mechanisms. It may affect swallowing as a result of nasal congestion, constant mouth breathing, throat dryness and pharyngitis.

Postoperative sore throat causes patient dissatisfaction and poor pain control. Several interventions could be performed to reduce sore throat and pharyngitis and increase patient satisfaction , which may not be convenient for all patients, such as gargling or sprays

Eligibility criteria: Inclusion Criteria:

* ASA I and II patients
* aged from 20 to 40 years old
* undergo septorhinoplasty

Exclusion Criteria:

* Bleeding disorders
* Uncontrolled hypertension
* Cardiovascular diseases
* Uncontrolled diabetes mellitus
* Collagen disorders
* Pregnancy

Primary outcomes:
measure: Sore throat
timeFrame: 48 hours postoperatively
Secondary outcomes:
measure: Dysphagia
timeFrame: 48 hours postoperatively
measure: Throat irritation
timeFrame: 48 hours postoperatively
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Neveen Kohaf
Study officials:
affiliation: Al-Azhar University
name: Neveen Kohaf, ph.d
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02414802: Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis
Official title: Study on the Application of a Novel Aspiration Thrombectomy Device Combined With Catheter-directed Thrombolysis for the Treatment of Acute Iliofemoral Deep Venous Thrombosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Venous Thrombosis
Lead sponsor: Xuzhou Medical University
Sponsor class: OTHER
First posted: 2015-04-13
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the novel aspiration thrombectomy device combined with catheter-directed thrombolysis is effective in the treatment of acute iliofemoral deep venous thrombosis (IF-DVT).

Detailed description: Catheter-directed thrombolysis will be performed in eligible patients with acute IF-DVT. A combined mechanical thrombectomy will be used to clear the iliac thrombi in experimental group. The immediate, mid- and long-term outcomes will be recorded. Quantitative data wiil be expressed as mean ± SD, and will be compared with independent-sample t-test or paired-sample t-test. Count data will be expressed as a ratio (or percentage), and the chi-square test or the fisher's exact test will be used for comparisons. A difference with P \< 0.05 will be considered statistically significant. All statistical analyses will be performed using IBM SPSS, version 22.0 (SPSS Inc., Chicago, IL, USA).

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of iliofemoral deep venous thrombosis
* Symptoms of less than 14 days' duration
* With good function status
* A life expectancy of more than 1 year
* A low risk of bleeding

Exclusion Criteria:

* Without iliac vein thrombosis
* Anticoagulation and/or thrombolysis contraindications
* Systemic infection
* Heart, hepatic, renal function insufficiency

Primary outcomes:
measure: patency of lower extremity deep venous
timeFrame: up to 36 months
Secondary outcomes:
measure: technical success rate
timeFrame: intraoperation
measure: thrombus removal rate
timeFrame: intraoperation
measure: complications
timeFrame: intraoperation
measure: blood loss
timeFrame: intraoperation
measure: improvement of clinical symptoms and signs
timeFrame: up to 36 months
Other outcomes:
measure: incidence of postthrombotic syndrome
timeFrame: up to 36 months
Locations:
city: Xuzhou
country: China
facility: Department of Interventional Radiology and Vascular Surgery, the Affiliated Hospital of Xuzhou Medical College
state: Jiangsu
Study officials:
affiliation: Xuzhou Medical University
name: Qingqiao Zhang, PHD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06868121: AYA OMGYES Sexual Health Study
Official title: Assessing the Impact of a Web-based Educational Program on the Sexual Health Outcomes of Young Adult Female Cancer Survivors ~ A Pilot Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Sexual Dysfunction
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2025-03-10
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to assess the impact of the web-based intervention OMGYES.com on sexual dysfunction in young adult (YA) female-bodied cancer survivors. This pilot trial seeks to evaluate the intervention's:

* feasibility
* acceptability
* appropriateness.

Researchers will utilize an active observation period to compare outcomes between those receiving the intervention immediately and those who haven't

Participants will:

* Complete online modules at home
* Visit the clinic every 5 weeks for questionnaires


Eligibility criteria: Inclusion Criteria:

* Age 18 to 40 years
* Diagnosis of cancer between the ages of 15 and 40
* Female genitalia, regardless of gender
* Diagnosed with sexual dysfunction
* Complete Remission and at least two months from a major treatment
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* Ability to participate in study modules and to respond to surveys
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Patients receiving other investigational agents
* Patients expected to be neutropenic or have a significantly high infection risk that would exclude them from vaginal penetration
* Patients who are unable complete the study intervention or surveys

Primary outcomes:
measure: Feasibility of OMGYES.com using the Feasibility of Intervention Measure (FIM)
timeFrame: End of Study (Week 6)
Secondary outcomes:
measure: Acceptability of OMGYES.com using the Acceptability of Intervention Measure (AIM)
timeFrame: End of Study (Week 6)
measure: Appropriateness of OMGYES.com using the Appropriateness of Intervention Measure
timeFrame: End of Study (Week 6)
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago Hospital
state: Illinois
Study officials:
affiliation: University of Chicago
name: Adam DuVall, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03102021: The Effect of Human Recombinant Erythropoietin in Acute Renal Failure
Official title: The Effect of High Dose Erythropoietin in Acute Renal Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Kidney Injury
Lead sponsor: North Texas Veterans Healthcare System
Sponsor class: FED
First posted: 2017-04-05
Enrollment: 25
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if the use of erythropoietin when used in high dose during acute kidney injury can decrease the number of days of kidney injury.

Detailed description: Acute kidney injury is associated with increased morbidity. The most common injury to the kidney occurs during hospitalization with either ischemic or nephrotoxic insult to the kidney. This can prolong hospitalization and depending on the severity of the insult result in permanent decreased kidney function. Recent studies in animals have suggested benefits of using erythropoietin in high doses at time of kidney injury with eividence for less injury in the kidney tissue of those animals who received treatment compared to those animals that received only saline. Limited human data also suggests that use of high dose erythropoietin at the time of stroke can decrease the extent of brain injury. In addition cardiac cell culture studies also have shown decrease in cell injury with use of erythropoietin. These studies have prompted us to evaluate if admininstering erythropoietin to those with onset of acute kidney injury during their hospitalization may benefit from this intervention. This pilot study then evaluates that use of high dose erythropoietin administed daily over 3 days in patients with acute kidney injury on whether the days spent in renal failure are less than those who will receive no study medication. Those patients with kidney failure from either ischemic or nephrotoxic insult and no other contraindication to erythropoietin use will be considered for the study. Informed consent is obtained from the patient or next of kin

Eligibility criteria: Inclusion Criteria:

* age equal or greater than 21 yo
* acute neprhotoxic or ischemic kidney injury, acute tubular necrosis

Exclusion Criteria:

* no active or current malignancies
* not actively receiveing epo
* GFR less than 60 ml/min
* unable to provide informed consent
* contraindication to erythropoietin use

Primary outcomes:
measure: days of acute renal failure
timeFrame: 28 days
Secondary outcomes:
measure: days of hospitalization
timeFrame: 60 days
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Dallas VAMC
state: Texas
Study officials:
affiliation: DAllas VA Medical Center/UT Southwestern Medical Center
name: Devasmita Dev, MD
role: PRINCIPAL_INVESTIGATOR
References: